| Literature DB >> 36257950 |
Olli P O Nevalainen1,2,3,4, Saana Horstia1, Sanna Laakkonen1, Jarno Rutanen2,5, Jussi M J Mustonen6, Ilkka E J Kalliala7,8, Hanna Ansakorpi9, Hanna-Riikka Kreivi10, Pauliina Kuutti1, Juuso Paajanen10, Seppo Parkkila11, Erja-Leena Paukkeri5, Markus Perola12,13, Negar Pourjamal1, Andreas Renner10,14, Tuomas Rosberg15, Taija Rutanen16, Joni Savolainen16, Jari K Haukka17,18, Gordon H Guyatt19,20, Kari A O Tikkinen21,22.
Abstract
We report the first long-term follow-up of a randomized trial (NCT04978259) addressing the effects of remdesivir on recovery (primary outcome) and other patient-important outcomes one year after hospitalization resulting from COVID-19. Of the 208 patients recruited from 11 Finnish hospitals, 198 survived, of whom 181 (92%) completed follow-up. At one year, self-reported recovery occurred in 85% in remdesivir and 86% in standard of care (SoC) (RR 0.94, 95% CI 0.47-1.90). We infer no convincing difference between remdesivir and SoC in quality of life or symptom outcomes (p > 0.05). Of the 21 potential long-COVID symptoms, patients reported moderate/major bother from fatigue (26%), joint pain (22%), and problems with memory (19%) and attention/concentration (18%). In conclusion, after a one-year follow-up of hospitalized patients, one in six reported they had not recovered well from COVID-19. Our results provide no convincing evidence of remdesivir benefit, but wide confidence intervals included possible benefit and harm.Entities:
Mesh：
Substances：
Year: 2022 PMID： 36257950 PMCID： PMC9579198 DOI： 10.1038/s41467-022-33825-5
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 17.694